Black Diamond Therapeutics shares surge 15.25% after-hours after announcing Phase 2 silevertinib trial data webcast.

Black Diamond Therapeutics surged 15.25% in after-hours trading following the announcement of a webcast scheduled for December 3, 2025, to present Phase 2 clinical trial results for silevertinib and provide an oncology program update. The company highlighted silevertinib’s potential as a fourth-generation EGFR inhibitor targeting EGFR-mutant non-small cell lung cancer and glioblastoma, emphasizing its brain-penetrant properties and ability to address resistance mechanisms. The event, accessible via the investor relations section of its website, generated immediate investor optimism about the drug’s therapeutic potential and pipeline progress. Other news, including price target adjustments and restructuring updates, were either older or unrelated to the after-hours rally. The webcast announcement directly aligned with the stock’s sharp rise, reflecting market anticipation of positive clinical data.